Reach Us +44-1647-403003
Tumor Specific Oligomeric Forms of Nucleophosmin | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Tumor Specific Oligomeric Forms of Nucleophosmin

Natalia M. Vladimirova1*, Maria A. Pisareva1, Oksana O. Zharskaya1, Natalia L. Deineko2, Tatiana I. Bulycheva2 and Olga M. Volpina1

1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow, 117997 Russia

2Hematology Research Center, Russian Ministry of Public Health, Novyi Zykovskii pr. 4a, Moscow, 125167 Russia

*Corresponding Author:
Dr. Natalia Vladimirova
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences
ul. Miklukho-Maklaya 16/10
117997 Moscow, Russia
E-mail: [email protected]

Received Date: September 30, 2011; Accepted Date: October 16, 2011; Published Date: October 18, 2011

Citation: Vladimirova NM, Pisareva MA, Zharskaya OO, Deineko NL, Bulycheva TI, et al. (2011) Tumor Specific Oligomeric Forms of Nucleophosmin. J Cancer Sci Ther 3: 205-212. doi:10.4172/1948-5956.1000090

Copyright: © 2011 Vladimirova NM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: According to recent data malignization of cells is accompanied not only by overexpression of protein B23/nucleophosmin, but also by formation of its new structural forms including unusual oligomers. The aim of this study was to evaluate the structural features of nucleophosmin in tumor cells. Materials and methods: Structural state of nucleophosmin was analyzed in different human tumor cells (HeLa, NGP, Hep G2, Osa-CL, Jurkat, Ramos, K-562) and human lymphocytes stimulated to proliferate by phytohemagglutinin. Commercially available monoclonal antibodies and new obtained by us antipeptide antibodies were used for analysis of monomer-oligomer state of nucleophosmin by immunochemical method and for determination of intracellular localization of monomers and oligomers by immunocytochemical method. Results: We revealed unusual SDS-resistant oligomeric forms of nucleophosmin in tumor cells of different type. Using protein chemistry strategy we showed the presence of truncated B23 isoforms in HeLa cells and their ability to form SDS-resistant oligomers. For the first time we created antipeptide antibodies which allowed differentiate monomeric and oligomeric nucleophosmin forms in tumor cells. Using these antibodies we showed different intracellular localization of monomers and oligomers in tumor cells. Conclusions: We propose that formation of SDS-resistant oligomeric forms of nucleophosmin is a common feature of human tumor cells and their detection with described antipeptide antibodies may be used for tumor diagnostics.


Share This Page